{"product_id":"new-product-614307","title":"Magnetic Luminex Assay Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc.","description":"\u003cp data-mce-fragment=\"1\"\u003eProduct No.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eLMN576Ra\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eOrganism Species\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eRattus norvegicus (Rat).\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSample Type\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSerum, plasma and other biological fluids.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eTest Method\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eDouble-antibody Sandwich\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eAssay Length\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e3.5h\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eDetection Range\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e0.2-200ng\/mL\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSensitivity\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eThe minimum detectable dose of this kit is typically less than 0.067 ng\/mL.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eUOM\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex.\u003c\/p\u003e\n\u003cdiv class=\"product_left\"\u003e\n\u003ch3\u003eSpecificity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThis assay has high sensitivity and excellent specificity for detection of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc..\u003cbr\u003eNo significant cross-reactivity or interference between Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. and analogues was observed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eRecovery\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eMatrices listed below were spiked with certain level of recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. in samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eRecovery range (%)\u003c\/td\u003e\n\u003ctd\u003eAverage(%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e85-93\u003c\/td\u003e\n\u003ctd\u003e89\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e98-105\u003c\/td\u003e\n\u003ctd\u003e101\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e91-99\u003c\/td\u003e\n\u003ctd\u003e95\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003esodium citrate plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e91-101\u003c\/td\u003e\n\u003ctd\u003e94\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003ePrecision\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. were tested 20 times on one plate, respectively.\u003cbr\u003eInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. were tested on 3 different plates, 8 replicates in each plate.\u003cbr\u003eCV(%) = SD\/meanX100\u003cbr\u003eIntra-Assay: CV\u0026lt;10%\u003cbr\u003eInter-Assay: CV\u0026lt;12%\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eLinearity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample\u003c\/td\u003e\n\u003ctd\u003e1:2\u003c\/td\u003e\n\u003ctd\u003e1:4\u003c\/td\u003e\n\u003ctd\u003e1:8\u003c\/td\u003e\n\u003ctd\u003e1:16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e96-104%\u003c\/td\u003e\n\u003ctd\u003e95-105%\u003c\/td\u003e\n\u003ctd\u003e86-96%\u003c\/td\u003e\n\u003ctd\u003e89-98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e92-105%\u003c\/td\u003e\n\u003ctd\u003e80-92%\u003c\/td\u003e\n\u003ctd\u003e92-104%\u003c\/td\u003e\n\u003ctd\u003e80-105%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e90-97%\u003c\/td\u003e\n\u003ctd\u003e81-96%\u003c\/td\u003e\n\u003ctd\u003e80-89%\u003c\/td\u003e\n\u003ctd\u003e83-97%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003esodium citrate plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e98-105%\u003c\/td\u003e\n\u003ctd\u003e94-101%\u003c\/td\u003e\n\u003ctd\u003e82-97%\u003c\/td\u003e\n\u003ctd\u003e79-99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003eStability\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\u003cbr\u003eTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eReagents and materials provided\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"reagent_div\"\u003e\n\u003ctable class=\"reagent_table\"\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e96-well plate\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePlate sealer for 96 wells\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Standard\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eStandard Diluent\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Magnetic beads (22#:FNDC5)\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eAnalysis buffer\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Detection Reagent A\u003c\/td\u003e\n\u003ctd\u003e1×120μL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent A\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent B (PE-SA)\u003c\/td\u003e\n\u003ctd\u003e1×120μL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent B\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSheath Fluid\u003c\/td\u003e\n\u003ctd\u003e1×10mL\u003c\/td\u003e\n\u003ctd\u003eWash Buffer (30 × concentrate)\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruction manual\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eAssay procedure summary\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003e1. Preparation of standards, reagents and samples before the experiment;\u003cbr\u003e2. Add 100μL standard or sample to each well,\u003cbr\u003e    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;\u003cbr\u003e3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;\u003cbr\u003e4. Wash plate on magnetic frame for three times;\u003cbr\u003e5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;\u003cbr\u003e6. Wash plate on magnetic frame for three times;\u003cbr\u003e7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes Research and Clinical Practice\u003c\/td\u003e\n\u003ctd\u003eSerum irisin levels in new-onset type 2 diabetes\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23369227\" target=\"_blank\"\u003ePubMed: 23369227\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of diabetes and its complications\u003c\/td\u003e\n\u003ctd\u003eLower circulating irisin is associated with type 2 diabetes mellitus\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23619195\" target=\"_blank\"\u003ePubmed: 23619195\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorm Metab Res.\u003c\/td\u003e\n\u003ctd\u003eInconsistency in circulating irisin levels: what is really happening\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24459033\" target=\"_blank\"\u003ePubmed:24459033\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInt J Obes (Lond).\u003c\/td\u003e\n\u003ctd\u003eLeptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25199621\" target=\"_blank\"\u003ePubmed:25199621\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular and Cellular Endocrinology\u003c\/td\u003e\n\u003ctd\u003eFenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25576856\" target=\"_blank\"\u003ePubmed:25576856\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ejournal of diabetes\u003c\/td\u003e\n\u003ctd\u003eLower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25494632\" target=\"_blank\"\u003ePubMed: 25494632\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThe Journal of Maternal-Fetal \u0026amp; Neonatal Medicine\u003c\/td\u003e\n\u003ctd\u003eMaternal circulating levels of irisin in intrahepatic cholestasis of pregnancy\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26689349\" target=\"_blank\"\u003ePubMed: 26689349\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHormone and Metabolic Research\u003c\/td\u003e\n\u003ctd\u003eLower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27300472\" target=\"_blank\"\u003ePubmed:27300472\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNature Reviews Endocrinology\u003c\/td\u003e\n\u003ctd\u003ePhysiology and role of irisin in glucose homeostasis.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28211512\" target=\"_blank\"\u003epubmed:28211512\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Molecular and Cellular Cardiology\u003c\/td\u003e\n\u003ctd\u003eIrisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1\/adiponectin axis in diet-induced obese mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27638193\" target=\"_blank\"\u003epubmed:27638193\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiochemical and Biophysical Research Communications\u003c\/td\u003e\n\u003ctd\u003eIrisin stimulates cell proliferation and invasion by targeting the PI3K\/AKT pathway in human hepatocellular carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28867187\" target=\"_blank\"\u003epubmed:28867187\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLoS One\u003c\/td\u003e\n\u003ctd\u003eDifferential actions of PPAR-α and PPAR-β\/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29351550\" target=\"_blank\"\u003ePubmed:29351550\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Brazilian Journal of Urology\u003c\/td\u003e\n\u003ctd\u003eThe Diagnostic Value of FNDC5\/Irisin in Renal Cell Cancer.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29522296\" target=\"_blank\"\u003ePubmed:29522296\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRedox Biology\u003c\/td\u003e\n\u003ctd\u003eIrisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213231718306347\" target=\"_blank\"\u003eDoi: 10.1016\/j.redox.2018.10.019\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntioxidants \u0026amp; redox signaling\u003c\/td\u003e\n\u003ctd\u003eLow serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.liebertpub.com\/doi\/abs\/10.1089\/ars.2019.7731\" target=\"_blank\"\u003ePubmed: 31250660\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Maternal-Fetal \u0026amp; Neonatal Medicine\u003c\/td\u003e\n\u003ctd\u003eMaternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31590596\/\" target=\"_blank\"\u003ePubmed: 31590596\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomed Pharmacother\u003c\/td\u003e\n\u003ctd\u003eIdentification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32199226\/\" target=\"_blank\"\u003ePubmed: 32199226\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eIrisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31976032\/\" target=\"_blank\"\u003ePubmed: 31976032\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eSerum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31976024\/\" target=\"_blank\"\u003ePubmed: 31976024\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDOMESTIC ANIMAL ENDOCRINOLOGY\u003c\/td\u003e\n\u003ctd\u003eThe myokine Irisin: localization and effects in swine late medium and large antral ovarian follicle\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33120167\/\" target=\"_blank\"\u003ePubmed: 33120167\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Biomaterials and Tissue Engineering\u003c\/td\u003e\n\u003ctd\u003eThe Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α\/Irisin\/UCP-1 Pathway\u003ca rel=\"nofollow\" href=\"https:\/\/www.ingentaconnect.com\/contentone\/asp\/jbte\/2019\/00000009\/00000010\/art00011\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eEvaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7\/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB\/c …\u003ca rel=\"nofollow\" href=\"https:\/\/doi.org\/10.1166\/mex.2020.1645\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEur Rev Med Pharmacol Sci\u003c\/td\u003e\n\u003ctd\u003eSalivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33755963\" target=\"_blank\"\u003e33755963\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolites\u003c\/td\u003e\n\u003ctd\u003ePattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34822430\/\" target=\"_blank\"\u003e34822430\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEat Weight Disord\u003c\/td\u003e\n\u003ctd\u003eTime-restricted feeding prevents metabolic diseases through the regulation of galanin\/GALR1 expression in the hypothalamus of mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34370270\/\" target=\"_blank\"\u003e34370270\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIr J Med Sci\u003c\/td\u003e\n\u003ctd\u003eEight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35604540\/\" target=\"_blank\"\u003ePubmed:35604540\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomed Pharmacother\u003c\/td\u003e\n\u003ctd\u003eIrisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35653888\/\" target=\"_blank\"\u003ePubmed:35653888\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of King Saud University - Science\u003c\/td\u003e\n\u003ctd\u003eInteraction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin …\u003ca rel=\"nofollow\" href=\"https:\/\/sciencedirect.53yu.com\/science\/article\/pii\/S1018364722001161\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Rattus norvegicus (Rat) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEN576Ra\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEN576Ra.html\"\u003eELISA Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMN576Ra\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LMN576Ra.html\"\u003eMagnetic Luminex Assay Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"0.2-200ng\/mL \/ 96T \/ typically less than 0.067 ng\/mL","offer_id":47566672888088,"sku":"LMN576Ra","price":912.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/LMN576Ra_7022cc00-7ec9-4373-a4d9-388987f83752.jpg?v=1705949827","url":"https:\/\/danabiosci.com\/products\/new-product-614307","provider":"Dana Bioscience","version":"1.0","type":"link"}